Schizophrenia Research
Volume 88, Issue 1 , Pages 102-110 , December 2006

Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study

  • Zhang-Jin Zhang

      Affiliations

    • Department of Psychiatry, The First Affiliated Hospital, Xi'an Jiaotong University College of Medicine, Xi'an, Shannxi 710061, China
    • The School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
    • Corresponding Author InformationCorresponding author. The School of Chinese Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, China. Tel.: +852 2589 0439; fax: +852 2872 5476.
    • ,
  • Wan-Hu Kang

      Affiliations

    • The School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
    • ,
  • Qiang Li

      Affiliations

    • The School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
    • ,
  • Xue-Yi Wang

      Affiliations

    • The School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
    • ,
  • Shao-Min Yao

      Affiliations

    • Mental Health Center and Department of Psychiatry, The First Teaching Hospital, Hebei Medical University, Shijiazhuang, Hebei 05003, China
    • ,
  • Ai-Qun Ma

      Affiliations

    • Mental Health Center and Department of Psychiatry, The First Teaching Hospital, Hebei Medical University, Shijiazhuang, Hebei 05003, China

Received 16 March 2006 ,Revised 12 July 2006 ,Accepted 14 July 2006.

References 

  1. Abi-Dargham A, Laruelle M, Wong DT, Robertson DW, Weinberger DR, Kleinman JE. Pharmacological and regional characterization of [3H]LY278584 binding sites in human brain. J. Neurochem. 1993;60:730–737
  2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. fourth edition. Washington, DC: American Psychiatric Association; 1994;
  3. Bell MD, Lysaker PH, Milstein RM, Beam-Goulet JL. Concurrent validity of the cognitive component of schizophrenia: relationship of PANSS scores to neuropsychological assessments. Psychiatry Res. 1994;54:51–58
  4. Briskin JK, Curtis JL. Augmentation of clozapine therapy with ondansetron. Am. J. Psychiatry. 1997;154:1171
  5. Broocks A, Little JT, Martin A, Minichiello MD, Dubbert B, Mack C, et al. The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls. Biol. Psychiatry. 1998;43:408–416
  6. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry. 2001;158:518–526
  7. Costall B, Naylor RJ. Pharmacological properties and functions of central 5-HT3 receptors. Therapie. 1991;46:437–444
  8. Costall B, Naylor RJ. 5-HT3 receptors. Curr. Drug Targets CNS Neurol. Disord. 2004;3:27–37
  9. Daneluzzo E, Arduini L, Rinaldi O, Di Domenico M, Petruzzi C, Kalyvoka A, et al. PANSS factors and scores in schizophrenic and bipolar disorders during an index acute episode: a further analysis of the cognitive component. Schizophr. Res. 2002;56:129–136
  10. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 2000;14:1–21
  11. Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr. Res. 2005;77:119–128
  12. Goff DC, Evins AE. Negative symptoms in schizophrenia: neurobiological models and treatment response. Harv. Rev. Psychiatry. 1998;6:59–77
  13. Guy W. ECDEU Assessment Manual for Psychopharmacology (revised). Bethesda, MD: US Department of Health, Education, and Welfare; 1976;
  14. Haus U, Spath M, Farber L. Spectrum of use and tolerability of 5-HT3 receptor antagonists. Scand. J. Rheumatol., Suppl. 2004;(119):12–18
  15. Javitt DC. Management of negative symptoms of schizophrenia. Curr. Psychiatry Rep. 2001;3:413–417
  16. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  17. Krausz M. Efficacy review of antipsychotics. Curr. Med. Res. Opin. 2002;18(S3):8–12
  18. Levkovitz Y, Arnest G, Mendlovic S, Treves I, Fennig S. The effect of Ondansetron on memory in schizophrenic patients. Brain Res. Bull. 2005;65:291–295
  19. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry. 2003;160:1396–1404
  20. Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. 1995;3:64–75
  21. Mohr PE, Cheng CM, Claxton K, Conley RR, Feldman JJ, Hargreaves WA, et al. The heterogeneity of schizophrenia in disease states. Schizophr. Res. 2004;71:83–95
  22. Parker RM, Barnes JM, Ge J, Barber PC, Barnes NM. Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain. J. Neurol. Sci. 1996;144:119–127
  23. Peuskens J, Demily C, Thibaut F. Treatment of cognitive dysfunction in schizophrenia. Clin. Ther. 2005;27(Suppl A):S25–S37
  24. Potvin S, Stip E, Roy JY. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int. Clin. Psychopharmacol. 2003;18:121–132
  25. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. Early psychosis global working group: risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry. 2005;162:947–953
  26. Sharma T. Impact on cognition of the use of antipsychotics. Curr. Med. Res. Opin. 2002;18(S3):s13–s17
  27. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr. Clin. North Am. 2003;26:25–40
  28. Sirota P, Mosheva T, Shabtay H, Giladi N, Korczyn AD. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am. J. Psychiatry. 2000;157:287–289
  29. Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr. Res. 2005;79:145–155
  30. Waeber C, Hoyer D, Palacios JM. 5-hydroxytryptamine3 receptors in the human brain: autoradiographic visualization using [3H]ICS 205-930. Neuroscience. 1989;31:393–400
  31. Waraich PS, Adams CE, Roque M, Hamill KM, Marti J. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database Syst. Rev. 2002;3:CD001951
  32. White A, Corn TH, Feetham C, Faulconbridge C. Ondansetron in treatment of schizophrenia. Lancet. 1991;337:1173
  33. Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry. 2001;62:878–883
  34. Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology. 1995;45:1305–1308

PII: S0920-9964(06)00317-3

doi: 10.1016/j.schres.2006.07.010

Schizophrenia Research
Volume 88, Issue 1 , Pages 102-110 , December 2006

Article Tools

* Image Usage & Resolution